Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study - Wikidata - awgldk - TriplyDB

Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study

Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study

http://www.wikidata.org/entity/Q36738155

about

Age-related immunity to meningococcal serogroup C vaccination: an increase in the persistence of IgG2 correlates with a decrease in the avidity of IgG Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy.Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity Impact of meningococcal C conjugate vaccination campaign in Emilia-Romagna, Italy.Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands.Identifying optimal vaccination strategies for serogroup A Neisseria meningitidis conjugate vaccine in the African meningitis belt.Meningococcal conjugate vaccines: optimizing global impact.Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009 Different Dynamics for IgG and IgA Memory B Cells in Adolescents following a Meningococcal Serogroup C Tetanus Toxoid Conjugate Booster Vaccination Nine Years after Priming: A Role for Priming Age?Single nucleotide polymorphisms in the Toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine.Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines.Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction Prospects for eradication of meningococcal disease Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.Kinetics of the natural, humoral immune response to Salmonella enterica serovar Typhi in Kathmandu, Nepal.Prevention of meningococcal serogroup C disease by NeisVac-C.Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy.Advances with vaccination against Neisseria meningitidis.Glycoconjugate vaccines.Glycoconjugate vaccines: an update.A review of guidance on immunization in persons with defective or deficient splenic function.Update on the use of meningococcal serogroup C CRM₁₉₇-conjugate vaccine (Meningitec) against meningitis.Kinetics of Meningococcal Serogroup C-Specific Functional Antibody Levels Up to 15 Years after a Single Immunization with a Meningococcal Serogroup C Conjugate Vaccine during Adolescence.Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults.Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients.The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012.Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study.Seroprotection against serogroup C meningococcal disease.Polysaccharide-protein conjugate vaccination induces antibody production but not sustained B-cell memory in the human nasopharyngeal mucosa.

P2860

Q28741100-852FA0A2-E575-404C-BA30-AB81C9C8C7CE Q28749695-A82F7236-700F-404C-B7B0-CC5CDB468E80 Q33397450-A92B2AED-80B6-4016-A750-BD49B4E20EE9 Q33806774-B2323C91-BCDD-41E8-9CF5-166A1110E9C7 Q33825722-644F6B8B-F536-4391-BDE8-EA16E26ADF43 Q34033849-FB119681-0A74-4645-B16B-C2F6AB097C9F Q34153704-07C960A1-2A5D-41BC-B851-72B6DBB3AFA1 Q34721179-3BBE1297-8D83-4033-A6F0-3A60A86A8AF5 Q35547767-E7951CEE-6625-4D27-B161-2B8F19BB7360 Q35598188-89D24B23-D90A-43EF-9DE7-BA6E918C6B83 Q35739057-A1FDD7A7-77FD-49E8-B4A5-A5C9A11C25DC Q35803424-D1BF1242-B891-426B-8F9D-CC7AA1AFC04F Q35805284-690C6088-74C3-4EDE-AF68-257E8587EB46 Q36083360-083F0FD0-CCB2-4FE2-B59F-8311E48EBB9E Q36154716-3964D1A9-68D4-4BC0-BAF8-BD4C9CB71944 Q36440358-381E776A-8E81-4398-B2D6-3FD7126A01AC Q36974336-93C2CCF1-E1BA-4DC0-8349-CFA50EA3DC02 Q37374692-58CA2CD4-C458-4669-8F7A-F20BD2363A41 Q37403478-447402EC-F161-4AEB-85A7-CC390A803408 Q37461347-4DEA8763-2B3B-4850-9476-B62C2A73D780 Q37878485-D946A521-4EF6-4385-A6AA-6755BF77C5F5 Q38040527-157F7700-336D-4C83-8CE1-4E60EB6A167A Q38044755-02C03600-C3D1-4AAE-B50F-B60F15680C01 Q38286346-DC65FF56-D932-4B70-9F52-3E62A7E3C9DD Q38575340-C9DCB693-701F-4956-8B58-1055ED18313D Q38631381-73FD9571-30AA-498F-A70A-C53C9466A251 Q38791439-01E17DD7-E266-4C80-AAD9-5FF1DD94B937 Q39809312-3BFCA379-B417-4691-9198-ADE2FF7B0F9A Q41488993-313C8157-C6A3-416C-8BA7-6B01D2C47D3D Q42204205-4A398077-507D-42C3-A3EA-954D09A658E9 Q42255158-2F4E3844-64CA-41FE-8A27-D396C9A5B3BD Q42270579-0DE93AA5-FA3A-48B3-B54C-F71320719EFA Q43077587-D2DD6C87-39AC-4AC4-AEC1-E1FB5C06A11B Q43876810-5B99671A-6FC6-4B86-BEEC-E64A9C0E1E1A

P2860

Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study

http://www.wikidata.org/entity/Q36738155

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Seroprotection against serogro ...... d Kingdom: observational study

@ast

Seroprotection against serogro ...... d Kingdom: observational study

@en

type

label

Seroprotection against serogro ...... d Kingdom: observational study

@ast

Seroprotection against serogro ...... d Kingdom: observational study

@en

prefLabel

Seroprotection against serogro ...... d Kingdom: observational study

@ast

Seroprotection against serogro ...... d Kingdom: observational study

@en

P1433

Q36738155-1311263D-88AE-45CE-9C4A-50C1B1F9FC0B

P1476

Q36738155-AE2B5758-3E12-499B-9CED-F56107EBF4AC

P2093

Q36738155-26C6CE7D-4B51-4BAD-B0E5-5FFDA986909F

Q36738155-350F8A06-6F04-461B-B9CE-865303643D1B

Q36738155-3C027488-B76C-4ABA-9DBB-75E3E30DF89A

Q36738155-438D5AD9-64B1-47D9-8E47-B810C7BB3C9F

Q36738155-4442D86B-0D32-4B76-BD09-A687F72A00B7

Q36738155-5D38D5DA-F475-4E93-B459-020D9C86E496

Q36738155-63C20816-89ED-45A1-BF48-4F680027420E

Q36738155-7A7E3E38-3EB2-4EF9-8024-75AD9E41463C

Q36738155-8C34E7C8-A134-48DD-8A9C-8921F16C824D

Q36738155-95A5F6C3-D76B-478D-B8D1-46030818435D

P2860

Q36738155-1A0677BE-BB97-4ABB-B6A5-02CF07D5F8C8

Q36738155-336F79E3-9B50-41EC-8056-A00F9EDA27D0

Q36738155-3CE98002-E9D4-4309-AFAA-8DB56FF7BFDF

Q36738155-3F4C12FB-BE2D-4FB6-9593-6CF73BB13F15

Q36738155-4747CBFC-64A4-4256-8807-98F11A78257B

Q36738155-49582938-F85D-4D43-974A-CD8747855B31

Q36738155-4C55189A-D321-42A0-B430-E58E91DB1898

Q36738155-4E61B412-A02D-4C5C-B0BB-E242A646D44D

Q36738155-4FF62D1D-CB20-4F26-9C5A-9059D0908CB4

Q36738155-553CBBA3-7A3A-4EFB-96A4-B9E2CBF040AF

P304

Q36738155-DFF3F528-1609-4908-8808-469B13384795

P31

Q36738155-EE8F6E0E-37F6-4B5D-AF60-DBDF51AA703E

P356

Q36738155-F162F471-2377-47DC-92E2-7121EEF904FD

P407

Q36738155-29C682E0-FDCD-4308-B7FF-6775DB662F9E

P433

Q36738155-8C9F32E9-4704-4ADB-ACFF-040305C42540

P478

Q36738155-D60468AB-E20D-48CE-9D1B-B737601328BB

P577

Q36738155-7546512B-0800-49FE-9383-E87392A4547E

P698

Q36738155-DA71FEC2-ED7C-4770-A2DF-B48CE27BE556

P921

Q36738155-F614F702-A8D6-4159-93DB-6B3ECBACC82B

P932

Q36738155-42E6DD9D-844C-4745-B644-214B41A30F2A

P356

BMJ.39563.545255.AE

P1433

P1476

Seroprotection against serogro ...... d Kingdom: observational study

@en

P2093

A Borkowski

http://www.w3.org/2001/XMLSchema#string

A J Pollard

http://www.w3.org/2001/XMLSchema#string

C Banner

http://www.w3.org/2001/XMLSchema#string

C E Moore

http://www.w3.org/2001/XMLSchema#string

C Nau

http://www.w3.org/2001/XMLSchema#string

D F Kelly

http://www.w3.org/2001/XMLSchema#string

L Diggle

http://www.w3.org/2001/XMLSchema#string

L Kibwana

http://www.w3.org/2001/XMLSchema#string

L M Yu

http://www.w3.org/2001/XMLSchema#string

M D Snape

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

Preventing varicella-zoster disease

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story.

Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection.

Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay.

Antigen dependent and independent mechanisms that sustain serum antibody levels.

Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants.

The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica.

Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population.

Cross-antigenicity and immunogenicity between capsular polysaccharides of group C Neisseria meningitidis and of Escherichia coli K92.

P304

1487-1491

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.39563.545255.AE

http://www.w3.org/2001/XMLSchema#string

P407

P433

7659

http://www.w3.org/2001/XMLSchema#string

P478

336

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18535032

http://www.w3.org/2001/XMLSchema#string

P921

P932

2440906

http://www.w3.org/2001/XMLSchema#string